r	Hits	Search Text	DB	Time stamp
	2612	("514/256,266.1").CCLS	USPAT	2004/04/20
	1840	("544/242,253,283,293").CCLS	USPAT	2004/04/20
	337	(("514/256,266.1").CCLS) and (("544/242,253,283,293").CCLS)	USPAT	2004/04/20
	75	((("514/256,266.1").CCLS) and (("544/242,253,283,293").CCLS)) and quinazoline	USPAT	2004/04/20
	2	((("514/256,266.1").CCLS) and (("544/242,253,283,293").CCLS)) and 7-amino	USPAT	2004/04/20
	5	((((("514/256,266.1").CCLS) and (("544/242,253,283,293").CCLS)) and quinazoline) and 4-amino	USPAT	2004/04/20

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:46:04 ON 20 APR 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 09:46:21 ON 20 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 16, 2004 (20040416/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 09:46:26 ON 20 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 09:46:35 ON 20 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9
DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10016280.18

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:47:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3965 TO ITERATE

100.0% PROCESSED 3965 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

L2 20 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 155.42 155.90

FILE 'MARPAT' ENTERED AT 09:47:14 ON 20 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 16)(20040416/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6706759 16 MAR 2004
DE 10335606 11 MAR 2004
EP 1396268 10 MAR 2004
JP 2004095205 25 MAR 2004
WO 2004022766 18 MAR 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:47:20 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 2733 TO ITERATE

100.0% PROCESSED 2733 ITERATIONS 93 ANSWERS
SEARCH TIME: 00.00.13

L3 93 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       109.42     265.32

FILE 'CAPLUS' ENTERED AT 09:47:44 ON 20 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Apr 2004  VOL 140 ISS 17
FILE LAST UPDATED: 19 Apr 2004  (20040419/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L4           70 L2

=> s l3
L5           93 L3

=> s l4 and l5
L6            3 L4 AND L5

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:833347  CAPLUS
DN   135:358167
TI   Preparation of peptides as thrombin inhibitors
IN   Kikelj, Danijel; Peterlin, Lucija; Marinko, Petra; Breznik, Matej;
     Stregnar, Mojca; Trampuz, Bakija Alenka; Fortuna, Marjana
PA   LEK Pharmaceutical & Chemical Co., Slovenia; University of Ljubljana;
     Browne, Robin Forsythe
SO   PCT Int. Appl., 106 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2001085760      A1   20011115       WO 2001-GB1997   20010504
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
```

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				SI 2000-111	A 20000505
SI 20582	C	20011231		SI 2000-111	20000505
EP 1287018	A2	20030305		EP 2001-925739	20010504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				SI 2000-111	A 20000505
				WO 2001-GB1997	W 20010504
US 2003191139	A1	20031009		US 2003-275215	20030131
				SI 2000-111	A 20000505
				WO 2001-GB1997	W 20010504

OS MARPAT 135:358167

IT **159382-23-7**, 4,6-Quinazolinediamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides as thrombin inhibitors)

RN 159382-23-7 CAPLUS

CN 4,6-Quinazolinediamine (9CI) (CA INDEX NAME)



IT **13741-90-7P**, 2,4,6-Quinazolinetriamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides as thrombin inhibitors)

RN 13741-90-7 CAPLUS

CN 2,4,6-Quinazolinetriamine (9CI) (CA INDEX NAME)



AB Compds. of D-CO-B-A-Het [Het is a heterocyclic moiety of defined structure, e.g., 5,6,7,8-tetrahydro-2-quinazolinamine, 4,5,6,7-tetrahydro-2H-indazol-2-ylamine, and 4,5,6,7-tetrahydro-1,3-benzothiazol-2-ylamine; A is CONH, CH2NH, CONHCH2, CH2NHCH2, CH2NHCONH, CH2NHCH2CONH, CH2NHCOCH2NH, CH2NHCONHCH2, CH2NHCH2CONHCH2 or CH2NHCOCH2NHCH2; B is 1,2-pyrrolidinediyl or 4-hydroxy derivative, 1,5-thiazolidinediyl, 1,2-piperidinediyl, NR3CHR4 (R3, R4 = H, C1-C4 alkyl, C3-C7 cycloalkyl); D is RcRdCH (Rc is NH2, alkylamino, hydroxyalkylamino, carboxyalkylamino, etc.; Rd is H, CH2OH, CH2CH2OH, alkyl

acceptable salts were prepared as thrombin inhibitors. Thus, (2S)-N-(2-amino-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl)-1-[(2R)-2-[(benzylsulfonyl)amino]-3-cyclohexylpropanoyl]-2-pyrrolidinecarboxamide, prepared by coupling of N-(benzylsulfonyl)-β-cyclohexyl-D-Ala-L-Pro-OH with 4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrobromide, showed Ki = 0.12 and >68.3 μM for inhibition of thrombin and trypsin, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:467270 CAPLUS
DN **125:168006**
TI Preparation of 2,4-diaminoquinazolines as insecticides
IN Henrie, Robert N., II; Peake, Clinton J.; Cullen, Thomas G.; Lew, Albert C.; Chaguturu, Munirathnam K.; Ray, Partha S.; Yeager, Walter H.; Silverman, Ian R.; Buser, John W.; et al.
PA FMC Corp., USA
SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 149,491, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5534518	A	19960709	US 1994-267340	19940628
				US 1993-19389	19930218
				US 1993-149491	19931109
	ZA 9401038	A	19940825	ZA 1994-1038	19940215
				US 1993-19389	19930218
	US 5616718	A	19970401	US 1995-426541	19950420
				US 1993-19389	19930218
				US 1993-149491	19931109
				US 1994-267340	19940628
	US 5874579	A	19990223	US 1996-640610	19960501
				US 1993-19389	19930218
				US 1993-149491	19931109
				US 1994-267340	19940628

PATENT FAMILY INFORMATION:
FAN 1994:695126

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418980	A1	19940901	WO 1994-US1658	19940217
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1993-19389	19930218
				US 1993-149491	19931109
	ZA 9401038	A	19940825	ZA 1994-1038	19940215
				US 1993-19389	19930218
	AU 9462986	A1	19940914	AU 1994-62986	19940217
				US 1993-19389	19930218
				US 1993-149491	19931109
				WO 1994-US1658	19940217
	EP 684824	A1	19951206	EP 1994-910684	19940217

US 1993-19389 19930218
US 1993-149491 19931109
WO 1994-US1658 19940217

OS MARPAT 125:168006

IT **13741-90-7P**, 2,4,6-Quinazolinetriamine
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-diaminoquinazolines as insecticides)

RN 13741-90-7 CAPLUS

CN 2,4,6-Quinazolinetriamine (9CI) (CA INDEX NAME)



IT **17511-20-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,4-diaminoquinazolines as insecticides)

RN 17511-20-5 CAPLUS

CN 2,4,6-Quinazolinetriamine, 5-chloro- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1,R6 = H or alkyl; R2,R7 = H, alkyl, alkanoyl, alkoxycarbonyl, etc.; R1R2 = O-interrupted alkylene; R1R2,R6R7 = dialkylaminomethylene, pyrrolidinomethylene, etc.; R3,R5,R6 = H halo, alkyl, alkoxy, etc.; R4 = H halo, alkyl, alkoxy, substituted aryl(oxy)

was converted in 4 steps to 2-amino-5-ethynyl-6-methylbenzonitrile which was arylated with 4-IC6H4CF3 and the product condensed with ClC(:NH)NH2.HCl to give title compound II which gave 90 and 100% kill of Trichoplusia ni and Spodoptera exigua, resp., at 30ppm foliar spray.

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:695126 CAPLUS
DN **121:295126**
TI Preparation of insecticidal substituted 2,4-diaminoquinazolines.
IN Henrie, Robert Neil, II; Peake, Clinton Joseph; Cullen, Thomas Gerard; Lew, Albert C.; Chaguturu, Munirathnam Krishnappa; Ray, Partha Sarathi
PA FMC Corp., USA
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418980	A1	19940901	WO 1994-US1658	19940217
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1993-19389	19930218
				US 1993-149491	19931109
	ZA 9401038	A	19940825	ZA 1994-1038	19940215
				US 1993-19389	19930218
	AU 9462986	A1	19940914	AU 1994-62986	19940217
				US 1993-19389	19930218
				US 1993-149491	19931109
				WO 1994-US1658	19940217
	EP 684824	A1	19951206	EP 1994-910694	19940217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI				
				US 1993-19389	19930218
				US 1993-149491	19931109
				WO 1994-US1658	19940217

PATENT FAMILY INFORMATION:
FAN 1996:467270

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5534518	A	19960709	US 1994-267340	19940628
				US 1993-19389	19930218
				US 1993-149491	19931109
	ZA 9401038	A	19940825	ZA 1994-1038	19940215
				US 1993-19389	19930218
	US 5616718	A	19970401	US 1995-426541	19950420
				US 1993-19389	19930218
				US 1993-149491	19931109
				US 1994-267340	19940628
	US 5874579	A	19990223	US 1996-640610	19960501
				US 1993-19389	19930218
				US 1993-149491	19931109
				US 1994-267340	19940628

OS MARPAT 121:295126
IT **13741-90-7P** 2,4,6-Quinazolinetriamine **17511-80-5P**

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of insecticidal diaminoquinazolines)

RN 13741-90-7 CAPLUS
CN 2,4,6-Quinazolinetriamine (9CI) (CA INDEX NAME)



RN 17511-20-5 CAPLUS
CN 2,4,6-Quinazolinetriamine, 5-chloro- (9CI) (CA INDEX NAME)



RN 17511-22-7 CAPLUS
CN 2,4,6-Quinazolinetriamine, 5-methyl- (9CI) (CA INDEX NAME)



RN 159018-74-3 CAPLUS
CN 2,4,6-Quinazolinetriamine, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



I

AB The title compds. I [R1= H, alkyl; R2,R3= R1, alkylcarbonyl, alkoxycarbonyl; R4 = H; R1R2= alkylenoxyalkylene; W, Y, Z = H,, halo, (halo)alkyl, (halo)alkoxy, (un)substituted thienyl or aroyl, etc.; X = H, halo, (halo)alkyl, NHCH2C6H4CO2H-4, etc.] are prepared as insecticides. 2-Amino-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]benzonitrile (preparation given) was reacted with chloroformamidine-HCl (preparation given) in diglyme, to yield 2,4-diamino-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]quinazoline (II). Diets containing 4% II were lethal to the tobacco budworm (Heliothis virescens).

```
=> d his

     (FILE 'HOME' ENTERED AT 09:46:04 ON 20 APR 2004)

     FILE 'STNGUIDE' ENTERED AT 09:46:21 ON 20 APR 2004

     FILE 'HOME' ENTERED AT 09:46:26 ON 20 APR 2004

     FILE 'REGISTRY' ENTERED AT 09:46:35 ON 20 APR 2004
L1              STRUCTURE UPLOADED
L2           20 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 09:47:14 ON 20 APR 2004
L3           93 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:47:44 ON 20 APR 2004
L4           70 S L2
L5           93 S L3
L6            3 S L4 AND L5

=> s l4 and quinazoline
L7          47 L4 AND QUINAZOLINE

=> s l7 and 7-cycloalkyl
L8           0 L7 AND 7-CYCLOALKYL

=> s l7 and cycloalkyl
L9           0 L7 AND CYCLOALKYL

=> s l5 and cycloalkyl
L10         21 L5 AND CYCLOALKYL

=> s l10 and quinazoline
L11          7 L10 AND QUINAZOLINE
```

L12 1 L4 AND CYCLOALKYL

=> d l11 fbib hitstr abs total

L11 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454316 CAPLUS
DN **139:36536**
TI Preparation of quinoline and **quinazoline** derivatives as inflammation modulators
IN Cushing, Timothy D.; He, Xiao; Smith, Marie-Louise; Degraffenreid, Michael R.; Powers, Jay; Tomooka, Craig S.; Clark, David L.; Hao, Xiaolin; Jaen, Juan C.; Labelle, Marc; Walker, Nigel P. C.; Gill, Adrian L.; Talamas, Francisco X.; Labadie, Sharada S.
PA Tularik Inc., USA; F. Hoffmann-La Roche AG
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048152	A2	20030612	WO 2002-US39134	20021204
	WO 2003048152	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-337460PP	20011205
	US 2003181472	A1	20030925	US 2002-314428	20021204
				US 2001-337460PP	20011205

OS MARPAT 139:36536
GI



I



II

alkynylene, CO, C:S, (un)substituted C:NH, NH, CONH, CSNH, C(:NH)NH, CH:N, O, S, S(O), SO2, alkylenamino, alkylenoxy; K = bond, alkylene, CO, CS, O, S, S(O), SO2, (un)substituted C:NH, NH; L = H, (un)substituted OH, alkyl, heteroalkyl, aryl, heteroaryl, NH2, acyl, thioacyl, CH:NH, carbamoyl, thiocarbamoyl, CO2H; JK, JL, KL = heterocyclic; B = 5-6-membered heteroarom.; R, R1 = H, halogen, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, NH2, **cycloalkyl**, heterocyclic, CN, NO2, acyl, alkoxycarbonyl, CONH2, SO2NH2] were prepared for use in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases. Thus, 5-chloroisatin was iodinated, cyclized with 5-acetyl-1-methyl-2-tert.-butyldimethylsilylimdazole, substituted with CH2:CHCN, reduced, and treated with 4-methylpyridine to give the quinoline II. I had IC50 ≤ 30 μM for inhibition of IKKβ.

L11 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:261684 CAPLUS
DN **138:287692**
TI Preparation of quinazolino- and quinolinoguanidines as ligands for neuropeptide FF (NPFF) receptors
IN Kawakami, Joel K.; Konkel, Michael J.; Boteju, Lakmal W.; Wetzel, John M.; Noble, Stewart A.; Wan, Honghe
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003026667	A1	20030403	WO 2002-US30259	20020924

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-963129 A 20010924

OS MARPAT 138:287692
GI



I



II

AB Title compds. I [X = CH, C(CH3), N; R1-5 = H, alk(en/yn)yl, **cycloalkyl**, aryl, etc.] are prepared For instance, 1,2-dibutoxy-4-nitrobenzene was reduced (MeOH, Cu(OAc)2, NaBH4) to the corresponding aniline and reacted with acetone (MgSO4, tert-butylcatechol, I2) to give 6,7-dibutoxy-2,2,4-trimethyl-1,2-dihydroquinoline. This intermediate was reacted with cyanoguanidine (HClaq, reflux) to give II. II has Ki = 303 nM for the rat neuropeptide FF1 (rNPFF1) receptor and Ki = 1299 nM for the rNPFF2 receptor. I are useful for the treatment of pain and incontinence.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:33802 CAPLUS
DN **138:89822**
TI Preparation of **quinazolines** and metabotropic glutamate receptor antagonists
IN Itahana, Hirotsune; Uekubo, Takashi; Nozawa, Shigenori; Kako, Hideki; Okada, Shoji; Totani, Atsushi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003012653	A2	20030115	JP 2001-196750	20010628
				JP 2001-196750	20010628

OS MARPAT 138:89822
GI



I

AB Metabotropic glutamate receptor antagonists comprise **quinazolines** I (R1 = H, halo, OH, lower alkyl, lower halogenoalkyl, etc.; R2 = XR7, N:R8; X = NR9, O, S, NR10CO, C(O), C(O)NR10, etc.; R7 = H, lower alkyl, (un)substituted, (un)bridged C6-10 **cycloalkyl**, (un)substituted saturated heterocyclyl; R8 = **cycloalkyl**; R9, R10 = H, lower alkyl; R7R9 may form (un)substituted saturated heterocyclyl; R3-R6 = halo, NO2, YR11; Y = single bond, O, NR12, S, lower alkylene, etc.; R11 = H, lower alkyl, heterocyclyl, aryl, **cycloalkyl**, etc.; R12 = H, lower alkyl) or their pharmaceutically acceptable salts. 4-Chloroquinazoline (150 mg) was treated with 187 mg thiomorpholine in the presence of CaCO3 in DMF at 60° and treated with HCl for 3 h to give 190 mg 4-(thiomorpholin-1-yl)**quinazoline** hydrochloride. I (R1 = R3-R6 = H, R2 = cyclohexylmethylamino) showed inhibition activity against binding mGluR1 with (6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide) with IC50 of 0.2 μm.

L11 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:240746 CAPLUS
DN **136:279468**
TI Preparation of 4-amino-**quinazolines** useful as glycoprotein IbIX antagonists, and their use for control of thrombotic disorders
IN Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Vickers, James; Cezanne, Bertram; Dhanoa, Daljit; Zhao, Bao-Ping; Rinker, James; Player, Mark R.; Jaeger, Edward; Soll, Richard
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002024667	A1	20020328	WO 2001-EP10705	20010917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2000-666908 A	20000920
AU 2001093817	A5	20020402	AU 2001-93817	20010917
			US 2000-666908 A	20000920
			WO 2001-EP10705W	20010917
EP 1318984	A1	20020618		

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2000-666908 A 20000920
WO 2001-EP10705W 20010917

BR 2001014020 A 20030722 BR 2001-14020 20010917
US 2000-666908 A 20000920
WO 2001-EP10705W 20010917

JP 2004509876 T2 20040402 JP 2002-529077 20010917
US 2000-666908 A 20000920
WO 2001-EP10705W 20010917

OS MARPAT 136:279468
GI



AB The preparation of 4-amino-**quinazolines** [I; wherein R, R1, independently = H, (C1-C6)alkyl, OH, (C1-C6)alkoxy, amino, nitro, cyano, etc.; R2,R3, independently = H,(C1-C6)alkyl, **cycloalkyl**, mono- or bicycloheterocyclic radical, etc.; R4 = aryl (e.g., Ph, naphthyl, biphenyl, etc.), or thiophen-2-yl substituted with aryl (as described supra) or heterocyclic radical, etc.; each of R, R1-R4 with many provisos] is described. Thus, [2-(4-bromophenyl)-7-chloroquinazolin-4-yl]-phenylamine was prepared by a multistep synthesis. The prepared compds. are useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders and sequelae deriving thereof.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:240745 CAPLUS
DN **136:279467**
TI Preparation of quinazolin-4-ylamines as glycoprotein IbIX antagonists.
IN Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Vickers, James; Cezanne, Bertram; Dhanoa, Daljit; Zhao, Bao-Ping; Rinker, James; Player, Mark R.; Jaeger, Edward; Soll, Richard
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002024666	A2	20020328	WO 2001-EP10704	20010917
WO 2002024666	A3	20020926		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2000-666117 A	20000920
AU 2002013923	A5	20020402	AU 2002-13923	20010917
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917
EP 1318985	A2	20030618	EP 2001-982300	20010917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917
BR 2001014021	A	20030819	BR 2001-14021	20010917
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917
JP 2004509875	T2	20040402	JP 2002-529076	20010917
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917
NO 2003001267	A	20030519	NO 2003-1267	20030319
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917
US 2004044204	A1	20040304	US 2003-380909	20030320
			US 2000-666117 A	20000920
			WO 2001-EP10704W	20010917

OS MARPAT 136:279467
GI



I

AB Title compds. [I; R, R1 = H, alkyl, halo, amino, NO2, cyano, allyl, (substituted) Ph, etc.; R2, R3 = H, alkyl, **cycloalkyl**, (substituted) heterocyclyl, hydroxyalkyl, etc.; NR2R3 = (substituted) heterocyclyl; R4 = (substituted) aryl, heterocyclyl; Y = (CH:CH)n; n = 1, 2; with provisos], were prepared for treatment of thrombotic disorders (no data). Thus, 4-chloro-2-(2-naphthalen-1-ylvinyl)**quinazoline** and 1,3-bis(aminomethyl)cyclohexane were heated in EtOH at 80° for 3 h to give 4-[N-(3-aminomethylcyclohexylmethyl)amino]-2-(2-naphthalen-1-ylvinyl)**quinazoline**.

L11 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:172597 CAPLUS
DN **130:209716**
TI Preparation of 2-vinyl-4-aminoquinazoline derivatives as insulin secretion promoters and antidiabetics
IN Ueno, Kimihisa; Nomoto, Yuji; Takasaki, Kotaro; Yoshida, Miho; Kusaka, Hideaki; Yano, Hiroshi; Nakanishi, Satoshi; Matsuda, Yuzuru; Uesaka,

PA Kyowa Hakko Kogyo Co., Ltd., Japan; et al.
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9909986	A1	19990304	WO 1998-JP3711	19980821
W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			JP 1997-225963	19970822
AU 9887487	A1	19990316	AU 1998-87487	19980821
			JP 1997-225963	19970822
			WO 1998-JP3711	19980821

OS MARPAT 130:209716
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Claimed are insulin secretion promoters and remedies for diabetes which contain as the active ingredient 2-vinyl-4-aminoquinazoline derivs. represented by general formula (I) or pharmacol. acceptable salts thereof [wherein R1A and R1B are the same or different and each represents hydrogen, lower alkyl, lower alkoxy, halogeno, nitro, NR3R4 (wherein R3 and R4 are the same or different and each represents hydrogen or lower alkyl), etc.; or R1A may form together with R1B adjacent thereto O(CH2)nO (wherein n is 1 or 2); Cy represents optionally substituted aryl; R2 represents hydrogen or optionally substituted lower alkyl; and A represents hydrogen or optionally substituted lower alkyl, optionally substituted **cycloalkyl**, etc.; or R2 and A may form together with the nitrogen atom adjacent thereto an optionally substituted heterocycle]. These compds. exhibited insulin secretion activity at high concentration of glucose (14.5 mM) but no substantial activity at low concentration of glucose (≤5 mM). For comparison, glubenclamide did exhibit substantial insulin-secretion activity at low concentration of glucose. Thus, 7-chloro-7-methoxy-2-[2-(E)-(2,4-dimethoxyphenyl)vinyl]**quinazoline** was condensed with N-methylphenethylamine to give the title compound (II). II in vitro showed insulin secretion activity of 3,413 ng/mL at 1 μM under 14.5 mM glucose and 86 ng/mL at 10 μM under 5 mM glucose in spleen β-cells (MIN6)as compared to that of 684 ng/mL at 0.1 μM under 14.5 mM glucose and 317 ng/mL at 0.1 μM under 5 mM glucose for glubenclamide.
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:495543 CAPLUS
DN **119:95543**
TI Preparation of annelated **quinazoline** derivatives as acetylcholinesterase inhibitors for treatment of cognitive deficiency
IN Gregor, Vlad Edward

SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9303034	A1	19930218	WO 1992-US5864	19920722
	W: AU, CA, CS, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
				US 1991-736888	19910729
				US 1992-911662	19920716
	CA 2113115	AA	19930218	CA 1992-2113115	19920722
				US 1991-736888	19910729
				US 1992-911662	19920716
	AU 9223978	A1	19930302	AU 1992-23978	19920722
	AU 665207	B2	19951221		
				US 1991-736888	19910729
				US 1992-911662	19920716
				WO 1992-US5864	19920722
	EP 597956	A1	19940525	EP 1992-916726	19920722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
				US 1991-736888	19910729
				US 1992-911662	19920716
				WO 1992-US5864	19920722
	HU 66324	A2	19941128	HU 1994-258	19920722
				US 1991-736888	19910729
				US 1992-911662	19920716
	CZ 281628	B6	19961113	CZ 1994-135	19920722
				US 1991-736888	19910729
				US 1992-911662	19920716
	ZA 9205660	A	19940128	ZA 1992-5660	19920728
				US 1991-736888	19910729
	FI 9400393	A	19940311	FI 1994-393	19940126
				US 1991-736888	19910729
				US 1992-911662	19920716
				WO 1992-US5864	19920722
	NO 9400305	A	19940328	NO 1994-305	19940128
				US 1991-736888	19910729
				US 1992-911662	19920716
				WO 1992-US5864	19920722
	US 5486512	A	19960123	US 1994-214911	19940317
				US 1991-736888	19910729
				US 1992-911662	19920716

OS MARPAT 119:95543
GI



AB Title compds. I; A = null, Q1-Q3, etc.; m = 0-10; n = 1-10; M = O, S, NR, :CRR1, RR1; X = null, 1-4 of halo, alkyl, alkenyl, alkynyl, (unsatd.) **cycloalkyl**, heterocyclyl, (hetero)aryl; amino, NO2, alkylthio, perfluoroalkyl, perfluoroalkoxy, heteroarylcarbonyl, etc.; Y = H, OH, CO2H, alkoxy, alkyl, aryl, heteroaryl, keto, alkoxycarbonyl, alkanoyl, etc.; Z = H, halo, alkyl, alkenyl, alkynyl, (unsatd.) **cycloalkyl**, heterocyclyl, heteroaryl, SH, OH, CO2H, carboalkoxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, etc.; R, R1 = H, OH, alkyl, alkenyl, alkynyl, OH, alkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl; RR1 = atoms to form a 3-6 membered (heterocyclic) ring], were prepared Thus, 4-chloroanthranilic acid was refluxed with 1-aza-2-methoxy-1-cycloheptene in C6H6 with azeotropic removal of H2O to give 76.7% 3-chloro-6,7,8,9-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one. This was heated with Zn/HOAc/HCl to give 3-chloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]**quinazoline**. This inhibited human red blood cell acetylcholinesterase with IC50 = 500 nM.

=> d his

(FILE 'HOME' ENTERED AT 09:46:04 ON 20 APR 2004)

FILE 'STNGUIDE' ENTERED AT 09:46:21 ON 20 APR 2004

FILE 'HOME' ENTERED AT 09:46:26 ON 20 APR 2004

FILE 'REGISTRY' ENTERED AT 09:46:35 ON 20 APR 2004
L1 STRUCTURE UPLOADED
L2 20 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 09:47:14 ON 20 APR 2004
L3 93 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:47:44 ON 20 APR 2004
L4 70 S L2
L5 93 S L3
L6 3 S L4 AND L5
L7 47 S L4 AND QUINAZOLINE
L8 0 S L7 AND 7-CYCLOALKYL
L9 0 S L7 AND CYCLOALKYL
L10 21 S L5 AND CYCLOALKYL
L11 7 S L10 AND QUINAZOLINE
L12 1 S L4 AND CYCLOALKYL

```
=> d l12 fbib hitstr ans total
'ANS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
```

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d his

     (FILE 'HOME' ENTERED AT 09:46:04 ON 20 APR 2004)

     FILE 'STNGUIDE' ENTERED AT 09:46:21 ON 20 APR 2004

     FILE 'HOME' ENTERED AT 09:46:26 ON 20 APR 2004

     FILE 'REGISTRY' ENTERED AT 09:46:35 ON 20 APR 2004
L1   STRUCTURE UPLOADED
L2   20 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 09:47:14 ON 20 APR 2004
L3   93 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:47:44 ON 20 APR 2004
L4   70 S L2
L5   93 S L3
L6   3 S L4 AND L5
L7   47 S L4 AND QUINAZOLINE
L8   0 S L7 AND 7-CYCLOALKYL
L9   0 S L7 AND CYCLOALKYL
L10   21 S L5 AND CYCLOALKYL
L11   7 S L10 AND QUINAZOLINE
L12   1 S L4 AND CYCLOALKYL

=>

=>

=>

=>

=>

=>

=>

=>

YOU HAVE RECEIVED 8 CONSECUTIVE ARROW PROMPTS (=>)
The arrow (=>) is the system prompt, where you enter a command. For an explanation of system commands, files, formats, etc., enter "HELP" and the name of the item you want explained at an arrow prompt (=>). Enter "HELP COMMANDS" for a list of commands that can be used in this file. Enter "HELP MESSAGES" for a list of online explanations that are available. The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message

After an error message, enter "HELP" or "?" at the next prompt and you will receive a more detailed explanation of the error and how to correct it.

Automatic help is also available. When AUHELP is 'ON', you will automatically receive help following an error message. For more information on AUHELP, enter "HELP SET AUHELP" at an arrow prompt (=>).

Users who need additional assistance can contact the Help Desk at their nearest STN Service Center. Enter "HELP STN" for information on STN Service Centers. You may also choose to contact the database representative for the file you are searching, for more detailed help on database content and search strategy. For information on how to contact database representatives for the current file, enter "HELP DESK" at an arrow prompt (=>).
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=>

=> d his

(FILE 'HOME' ENTERED AT 09:46:04 ON 20 APR 2004)

```
     FILE 'HOME' ENTERED AT 09:46:26 ON 20 APR 2004

     FILE 'REGISTRY' ENTERED AT 09:46:35 ON 20 APR 2004
L1              STRUCTURE UPLOADED
L2           20 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 09:47:14 ON 20 APR 2004
L3           93 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:47:44 ON 20 APR 2004
L4           70 S L2
L5           93 S L3
L6            3 S L4 AND L5
L7           47 S L4 AND QUINAZOLINE
L8            0 S L7 AND 7-CYCLOALKYL
L9            0 S L7 AND CYCLOALKYL
L10          21 S L5 AND CYCLOALKYL
L11           7 S L10 AND QUINAZOLINE
L12           1 S L4 AND CYCLOALKYL

=> d l12 fbib hitstr abs total

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:833347  CAPLUS
DN   135:358167
TI   Preparation of peptides as thrombin inhibitors
IN   Kikelj, Danijel; Peterlin, Lucija; Marinko, Petra; Breznik, Matej;
     Stregnar, Mojca; Trampuz, Bakija Alenka; Fortuna, Marjana
PA   LEK Pharmaceutical & Chemical Co., Slovenia; University of Ljubljana;
     Browne, Robin Forsythe
SO   PCT Int. Appl., 106 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2001085760     A1    20011115      WO 2001-GB1997   20010504
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           SI 2000-111    A 20000505
     SI 20582          C     20011231      SI 2000-111      20000505
     EP 1287018        A2    20030305      EP 2001-925739   20010504
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           SI 2000-111    A 20000505
                                           WO 2001-GB1997 W 20010504
     US 2003191139     A1    20031009      US 2003-275215   20030131
                                           SI 2000-111    A 20000505
```

OS MARPAT 135:358167

IT **159382-23-7**, 4,6-Quinazolinediamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides as thrombin inhibitors)

RN 159382-23-7 CAPLUS

CN 4,6-Quinazolinediamine (9CI) (CA INDEX NAME)



IT **13741-90-7P**, 2,4,6-Quinazolinetriamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides as thrombin inhibitors)

RN 13741-90-7 CAPLUS

CN 2,4,6-Quinazolinetriamine (9CI) (CA INDEX NAME)



AB Compds. of D-CO-B-A-Het [Het is a heterocyclic moiety of defined structure, e.g., 5,6,7,8-tetrahydro-2-quinazolinamine, 4,5,6,7-tetrahydro-2H-indazol-2-ylamine, and 4,5,6,7-tetrahydro-1,3-benzothiazol-2-ylamine; A is CONH, CH2NH, CONHCH2, CH2NHCH2, CH2NHCONH, CH2NHCH2CONH, CH2NHCOCH2NH, CH2NHCONHCH2, CH2NHCH2CONHCH2 or CH2NHCOCH2NHCH2; B is 1,2-pyrrolidinediyl or 4-hydroxy derivative, 1,5-thiazolidinediyl, 1,2-piperidinediyl, NR3CHR4 (R3, R4 = H, C1-C4 alkyl, C3-C7 **cycloalkyl**); D is RcRdCH (Rc is NH2, alkylamino, hydroxyalkylamino, carboxyalkylamino, etc.; Rd is H, CH2OH, CH2SH, alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl)] or their pharmaceutically acceptable salts were prepared as thrombin inhibitors. Thus, (2S)-N-(2-amino-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl)-1-[(2R)-2-[(benzylsulfonyl)amino]-3-cyclohexylpropanoyl]-2-pyrrolidinecarboxamide, prepared by coupling of N-(benzylsulfonyl)-β-cyclohexyl-D-Ala-L-Pro-OH with 4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrobromide, showed Ki = 0.12 and >68.3 μM for inhibition of thrombin and trypsin, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.07	221.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.62	-7.62

STN INTERNATIONAL LOGOFF AT 09:52:56 ON 20 APR 2004